KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Outstanding (Diluted Average): 2018-2024

Historic Shares Outstanding (Diluted Average) for Amneal Pharmaceuticals (AMRX) over the last 6 years, with Dec 2024 value amounting to $309.0 million.

  • Amneal Pharmaceuticals' Shares Outstanding (Diluted Average) rose 4.88% to $324.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $324.8 million, marking a year-over-year increase of 4.88%. This contributed to the annual value of $309.0 million for FY2024, which is 75.42% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Shares Outstanding (Diluted Average) is $309.0 million, which was up 75.42% from $176.1 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $309.0 million in FY2024 and a low of $148.9 million during FY2020.
  • In the last 3 years, Amneal Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $176.1 million in 2023 and averaged $212.0 million.
  • Data for Amneal Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 75.42% (in 2024) over the last 5 years.
  • Amneal Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $148.9 million in 2020, then reached $150.9 million in 2022, then grew by 16.69% to $176.1 million in 2023, then spiked by 75.42% to $309.0 million in 2024.